Key Drivers
- Zero Debt
- Strong Liquidity
- Margin Moderation
AIAI Summary
UTHR is a financially durable but increasingly execution-dependent investment: its debt-free, cash-generative Tyvaso franchise funds major upside from IPF Tyvaso and ralinepag, yet slowing core revenue and heavier spending mean the thesis now hinges on successful 2027 FDA approvals and commercialization rather than legacy growth. Investors should view current weakness as an opportunity only if they can tolerate binary regulatory risk and potential margin pressure ahead of those catalysts.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Zero Debt
- •Strong Liquidity
- •Margin Moderation
UTHR is financially strong with exceptional margins, cash generation, liquidity, and zero debt, but recent margin moderation, lower equity, and no dividend warrant a balanced stance.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support test
- •Weak momentum
UTHR is bearish over the last month, with support at $487.61–$490.24 and a recovery requiring a sustained move above $500–$504.
No unusual price movement; steady decline of roughly 5%
Sentiment & News
Key News Insights:
- •FDA Application Progress
- •Accelerated Buyback
- •Mixed Trading Signals
United Therapeutics' FDA filings and buyback strengthen its growth outlook, though recent share weakness, insider sales, and mixed institutional activity warrant caution.
Regulatory momentum and capital returns are positive catalysts, but near-term volatility may persist
Similar Companies in Healthcare
Other companies in the same sector with AI ratings